Aethlon Medical, Inc.

AEMD

CIK 0000882291 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$44K
↓-26.8% -$16Kvs FY2024 (Q4)
Gross Profit
$44K
↓-26.8% -$16Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -135.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.13 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.00x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -26.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -4700.4% · trend -2633.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$290K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$8M
everything owned
Total liabilities
$1M
everything owed
Stockholders' equity
$7M
shareholder claim

Recent performance · 63 quarters

Revenue↓-26.8% -$16K
$44K
Net Income↓-15.0% -$263K
$-2M
Free Cash Flow↑+1.9% +$33K
$-2M
Operating Margin↓-1674.0pts
-4700.4%

Drill down